The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
 
Blossom Mak
No Relationships to Disclose
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Hayley Thomas
No Relationships to Disclose
 
Farzana Pashankar
Consulting or Advisory Role - Novartis
 
Aaron Hansen
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; Janssen; Merck
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Darren Feldman
Consulting or Advisory Role - BioNTech; Debiopharm Group; Exelixis; Renibus Therapeutics; Telix Pharmaceuticals; Xencor
Research Funding - Bristol-Myers Squibb/Roche; Decibel Therapeutics (Inst); Exelixis; Telix Pharmaceuticals
Other Relationship - UpToDate
 
Robert Huddart
Leadership - Cancer clinic london Limited liability partnership
Consulting or Advisory Role - Bayer; BioNTech SE; Gilead Sciences; Janssen; Janssen Oncology; Merck; Merck Sharp & Dohme; Nektar; Roche
Speakers' Bureau - Bristol Myers Squibb Foundation; Pfizer
Research Funding - Astellas Pharma (Inst); Basilea (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst)
Travel, Accommodations, Expenses - Janssen; Nektar; Roche/Genentech
 
Matthew Wheater
Honoraria - Delcath Systems; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; bristol-Myers Squibb; Delcath systems; Ipsen
Research Funding - AVEO (Inst); Bristol-Myers Squibb/Medarex (Inst); Delcath Systems (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); MSD (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; Novartis
 
Elaine Dunwoodie
No Relationships to Disclose
 
Danish Mazhar
No Relationships to Disclose
 
Nicola Lawrence
Employment - Canopy Cancer Care
Stock and Other Ownership Interests - Canopy Cancer Care
 
Amanda Stevanovic
No Relationships to Disclose
 
Alison Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Bristol-Myers-Squib; Janssen Oncology; Merck Serono; Pfizer; Roche; Sanofi
Speakers' Bureau - Bayer; Janssen Oncology; Merck; Pfizer
Research Funding - Genzyme
 
Olabode Oladipo
Consulting or Advisory Role - Bristol-myers squibs UK
 
David Wyld
Research Funding - Ipsen (Inst)
 
Jay Michael Balagtas
No Relationships to Disclose
 
Martin Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Tilray (Inst)
 
Peter Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Genentech (Inst); InhibRx (Inst); InhibRx (Inst); Janssen-Cilag (Inst); MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
No Relationships to Disclose